Table 3.
Uni- and Multi-variate analysis of overall survival and 5-year progression free survival in patients with ovarian cancer (n = 110).
| Overall Survival |
5-year Progression free survival |
|||||
|---|---|---|---|---|---|---|
| Crude HR (95% CI) | Adjusted HR (95% CI) | Statistical significance | Crude HR (95% CI) | Adjusted HR (95% CI) | Statistical significance | |
| FIGO stage (III/IV vs I/II) | 2.52 (1.16–5.49) | 2.63 (1.27–5.46) | P = 0.010 | 10.31 (2.30–40.31) | 11.99 (2.75–52.20) | P = 0.001 |
| Nuclear GPR30 (positive vs negative) | 1.80 (1.06–3.06) | 1.75 (1.04–2.93) | P = 0.035 | 1.83 (0.96–3.46) | – | ns |
| Cytoplasmic GPR30 (positive vs negative) | 1.30 (0.95–6.99) | – | ns | 0.97 (0.54–1.76) | – | ns |
| Nuclear grading (high vs low) | 1.22 (0.69–2.17) | – | ns | 1.26 (0.60–2.66) | – | ns |
| Age (≥60y vs <60y) | 1.02 (1.02–1.04) | 1.03 (1.01–1.05) | P = 0.001 | 1.01 (0.98–1.03) | – | ns |
Hr, Hazard ratio; CI, confidence interval; FIGO, International Federation of Gynaecology and Obstetrics staging system (I/II = low/moderate grade tumours, III/IV = high grade/undifferentiated)